Targeting splicing in myelodysplasia through GSK-3
Targeting splicing in myelodysplasia through GSK-3
批准号:
10677505
负责人:
PETER S KLEIN
金额:
$10.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-16 至 2023-08-31
关键词:
AddressAlternative SplicingApoptosisCASP8 geneCASP9 geneCell DeathCell LineCellsClinicalDataDiseaseDrug usageDysmyelopoietic SyndromesFlow CytometryFutureGlycogen Synthase Kinase 3GoalsHematopoieticHumanK-562MeasuresMessenger RNAMutationNeoplasmsPathogenicityPatientsProtein FamilyRNA SplicingRecurrenceRoleSRSF2 geneSignal TransductionSignaling ProteinSomatic MutationSystemTestingTherapeuticWestern Blottingexperimental studygain of function mutationin vivoinhibitormutantnovelnovel strategiesnovel therapeutic interventionside effectsmall moleculetherapeutic target
中文摘要
(请保存在Word中,不要保存为PDF)
剪接因子SRSF2和SF3B1的反复突变在骨髓发育不良中很常见
(MDS)。这些功能突变的获得是相互排斥的,并且总是杂合的,
这表明具有剪接因子突变的细胞需要一些野生型剪接活性来
活下去。剪接设备的进一步扰动是致命的,造成了治疗的脆弱性
用于剪接因子突变的肿瘤。因此,小分子剪接抑制剂目前正在被
探索过治疗剪接因子突变的MDS,但它们有不可耐受的副作用和
到目前为止效果有限,这表明需要新的方法来抑制剪接。我们发现
信号蛋白糖原合成酶-3(GSK-3)磷酸化多剪接
影响和调节广泛的mRNAs的选择性剪接。GSK-3的抑制作用
在杂合子的造血细胞系中选择性地破坏剪接和促进细胞死亡
SRSF2或SF3B1突变。我们的长期目标是将GSK-3定义为
新型的全球剪接调控因子并测试GSK-3抑制剂是否具有选择性
对带有剪接因子突变的MDS细胞来说,体内是致命的。我们的初步数据支持这一点
在造血细胞系中的假说,但重要的是在原代建立这些发现
MDS和CMML患者的人类细胞。我们将表达SRSF2wt或致病性
MDS患者原代细胞中SRSF2P95H突变是否表达
致病突变赋予了对GSK-3抑制的敏感性,在其他相同的基因背景下。
这些实验将提供关键的初步数据,并为以后的工作奠定基础
研究GSK-3作为全球剪接调节因子和作为潜在调控因子的作用的实验
剪接因子突变体MDS的治疗靶点。
英文摘要
(PLEASE KEEP IN WORD, DO NOT PDF)
Recurrent mutations in the splicing factors SRSF2 and SF3B1 are common in myelodysplasia
(MDS). These gain of function mutations are mutually exclusive and invariably heterozygous,
indicating that cells with splicing factor mutations require some wild-type splicing activity to
survive. Further perturbation of the splicing apparatus is lethal, creating a therapeutic vulnerability
for splicing factor mutant neoplasms. Thus, small molecule splicing inhibitors are currently being
explored to treat splicing factor mutant MDS, but they have had intolerable side effects and
limited efficacy so far, indicating that new approaches to inhibit splicing are needed. We found
that the signaling protein glycogen synthase kinase-3 (GSK-3) phosphorylates multiple splicing
factors and regulates the alternative splicing of a broad range of mRNAs. Inhibition of GSK-3
disrupts splicing and promotes cell death selectively in hematopoietic cell lines with heterozygous
mutations in SRSF2 or SF3B1. Our long-term goals are to define the role of GSK-3 as a
novel, global regulator of splicing and to test whether GSK-3 inhibitors are selectively
lethal in vivo for MDS cells with splicing factor mutations. Our preliminary data support this
hypothesis in hematopoietic cell lines, but it is important to establish these findings in primary
human cells from patients with MDS and CMML. We will express SRSF2wt or the pathogenic
SRSF2P95H mutation in primary cells from patients with MDS to ask whether expression of the
pathogenic mutation confers sensitivity to GSK-3 inhibition in an otherwise isogenic context.
These experiments will provide critical preliminary data and lay the groundwork for future
experiments to investigate the role of GSK-3 as a global regulator of splicing and as a potential
therapeutic target in splicing factor mutant MDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular mechanisms of lithium action on kinases
-
批准号:10705786
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2022
-
负责人:PETER S KLEIN
-
依托单位:
Molecular mechanisms of lithium action on kinases
-
批准号:10500972
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2022
-
负责人:PETER S KLEIN
-
依托单位:
Targeting Coronavirus through Nucleocapsid Phosphorylation
-
批准号:10239590
-
项目类别:
-
资助金额:$44.69万
-
财政年份:2021
-
负责人:PETER S KLEIN
-
依托单位:
Maintenance and expansion of long-term hematopoietic stem cells
-
批准号:9767274
-
项目类别:
-
资助金额:$54.03万
-
财政年份:2018
-
负责人:PETER S KLEIN
-
依托单位:
The Penn-StARR Program for Research in Residency
-
批准号:10321397
-
项目类别:
-
资助金额:$34.94万
-
财政年份:2018
-
负责人:PETER S KLEIN
-
依托单位:
Maintenance and expansion of long-term hematopoietic stem cells
-
批准号:10162647
-
项目类别:
-
资助金额:$54.03万
-
财政年份:2018
-
负责人:PETER S KLEIN
-
依托单位:
An unexpected signaling output for the tumor suppressor APC
-
批准号:9353834
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2016
-
负责人:PETER S KLEIN
-
依托单位:
An unexpected signaling output for the tumor suppressor APC
-
批准号:9753259
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2016
-
负责人:PETER S KLEIN
-
依托单位:
An unexpected signaling output for the tumor suppressor APC
-
批准号:9504746
-
项目类别:
-
资助金额:$8.29万
-
财政年份:2016
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of Neurogenesis and Behavior by GSK-3
-
批准号:9001371
-
项目类别:
-
资助金额:$45.76万
-
财政年份:2014
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of Neurogenesis and Behavior by GSK-3
-
批准号:8652557
-
项目类别:
-
资助金额:$52.06万
-
财政年份:2014
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of Neurogenesis and Behavior by GSK-3
-
批准号:8791140
-
项目类别:
-
资助金额:$45.21万
-
财政年份:2014
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of neurogenesis and behavior by GSK-3
-
批准号:8665030
-
项目类别:
-
资助金额:$39.1万
-
财政年份:2013
-
负责人:PETER S KLEIN
-
依托单位:
Targeting Wnt and mTOR to expand hematopoietic stem cells
-
批准号:8088551
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8210662
-
项目类别:
-
资助金额:$54.3万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Targeting Wnt and mTOR to expand hematopoietic stem cells
-
批准号:8248167
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8461299
-
项目类别:
-
资助金额:$50.23万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8656762
-
项目类别:
-
资助金额:$51.3万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8304987
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Early activation of the zygotic genome
-
批准号:7145079
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2006
-
负责人:PETER S KLEIN
-
依托单位:
海外基金